Q-omics provides the consensus-scored MED13L profile across patient tissues and cancer cell-line models. MED13L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MED13L is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, MED13L protein abundance shows 22,886 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where MED13L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED13L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED13L survival associations across molecular data types. MED13L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED13L RNA expression–survival associations across cancer types. High MED13L expression shows unfavorable associations in OV and LIHC, but favorable associations in KIRC, UCS, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MED13L RNA expression.
This table summarizes MED13L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MED13L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED13L shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, HNSC, CHOL and LIHC. The THCA box plot shows higher MED13L RNA expression in normal versus tumor tissue (log2 FC = −1.056, t-test p < 0.001).
This table shows molecular features associated with MED13L in patient tissues and cancer cell lines. In patient samples, MED13L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED13L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
